US FDA approves first RSV vaccine from GSK
The U.S. Food and Drug Administration has approved GSK Plc’s (GSK.L) respiratory syncytial virus (RSV) vaccine, the British drugmaker said on Wednesday, making it the first shot to be cleared for protection against a common respiratory disease that can be fatal for older people. The vaccine, Arexvy, was approved for people aged 60 and older, the company…